ARA-290 (Cibinetide) is a groundbreaking synthetic peptide that effectively reduces neuropathic pain and enhances nerve regeneration without increasing red blood cell production. Currently making waves in clinical trials, it's showing remarkable results in treating diabetic neuropathy and pain associated with sarcoidosis.
Mechanism
ARA-290 activates the Innate Repair Receptor (IRR), a unique receptor complex combining the erythropoietin receptor (EPOR) with the beta common receptor (CD131). This powerful activation triggers tissue protection, reduces inflammation, and promotes nerve regeneration, safeguarding organs from ischemic injury.
Research
Phase II clinical trials reveal ARA-290 significantly alleviates neuropathic symptoms, with up to a 40% decrease in pain scores in diabetic neuropathy patients and substantial nerve fiber regeneration in those suffering from sarcoidosis. These outcomes are further supported by a strong safety and tolerability profile.
Synergies
Collaborative benefits with other neuroprotective agents and anti-inflammatory supplements are possible. Ben IQ will assess YOUR labs and goals to tailor the optimal stack for you.
Trade-Offs
These insights are general; YOUR individual circumstances require personalized data for effective assessment.